Myriad Genetics Using BRACAnalysis as CDx for Tesaro Cancer Drug | GenomeWeb Daily News | Clinical Genomics | GenomeWeb

Blogger's Note: register to view (free)

GenomeWeb

June 24, 2013

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Monday that it has signed an agreement to provide its BRACAnalysis test as a companion diagnostic for a cancer therapeutic being developed by Tesaro.
Under the terms of the deal, the BRCA1 and BRCA 2 test will be used in two separate Phase III clinical trials with niraparib, a novel, orally active poly (ADP ribose) polymerase, or PARP, inhibitor. One trial, in platinum-sensitive, high-grade serous ovarian cancer patients, is slated to begin enrollment in the middle of this year. A second trial, in metastatic breast cancer patients who have germline BRCA mutations, will begin in the second half of the year........